- Poster presentation
- Open Access
Adrenaline auto-injector prescription and patients’ administration proficiency
© Amaral et al; licensee BioMed Central Ltd. 2015
- Published: 30 March 2015
- Emergency Department
- Training Session
- Food Allergy
- Life Situation
Adrenaline is the first-line emergency treatment for anaphylaxis. The only adrenaline auto-injector (AAI) currently available in Portugal is Anapen®. The aim of this study was to evaluate adrenaline prescription in the Emergency Department (ED) and the patients' capacity to correctly simulate adrenaline administration.
Patients with food allergy (FA) and hymenoptera venom allergy (HVA) followed in our department were invited to simulate adrenaline administration with an Anapen® trainer and a medical record review was performed.
A total of 36 individuals (50% male, mean age 34.5 years) were included; 28 with HVA (26 on venom immunotherapy) and 8 with FA. Twenty-seven went to an ED. Adrenaline was administered in only 3 and just5 of them were discharged with an AAI prescription. The remaining 22 had their AAI prescribed and taught how to use it, only after consultation with an Allergist. Twenty-three (64%) had their Anapen® with them and 19 (53%) admitted carrying it on a daily basis. Fourteen (39%) performed the simulation correctly, although 7 of them did not massage the injection site, as instructed by the manufacturer. On average, 2 training sessions were performed per patient but, despite this, 22 (61%) failed at various steps, including 4 who injected with the wrong end. Six reported using their Anapen® in a real life situation, but curiously 4 of them did not simulate the administration effectively.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.